Participants 62 138 5
patients with standard-risk disease following haploidentical transplantation
Participants 259 430 7
acute GVHD among patients receiving hematopoietic SCT without ex vivo T-cell-depletion from haploidentical donors, 224 patients with standard-risk hematological malignancy
Participants 462 568 3
One hundred and twelve patients received 6 mg/kg ATG, whereas the remaining patients received 10 mg/kg
